Bioarray Genetics has received $4 million in Series B Equity Financing from Quark Venture and GF Securities through their Global Health Science Fund and Connecticut Innovations.

Bioarray will use this funding to bring their first product, BA100, to clinicians and conduct R&D on other tests in the company’s pipeline.

BA100 is a breast cancer diagnostic test that provides actionable information about patient response to the standard of care chemotherapy treatment. BA100 is able to identify the population of triple negative breast cancer patients that have the worst survival rates and would benefit from more aggressive treatment.

more